Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Dow
McKesson
Colorcon
McKinsey

Last Updated: January 28, 2023

Investigational Drug Information for Deoxythymidine


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Deoxythymidine?

Deoxythymidine is an investigational drug.

There have been 10 clinical trials for Deoxythymidine. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2021.

The most common disease conditions in clinical trials are HIV Infections, Infections, and Infection. The leading clinical trial sponsors are National Institute of Allergy and Infectious Diseases (NIAID), Zogenix, Inc., and Modis Therapeutics, Inc.

There are two hundred and twenty-three US patents protecting this investigational drug and twenty-nine international patents.

Recent Clinical Trials for Deoxythymidine
TitleSponsorPhase
Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal CancerFondazione IRCCS Istituto Nazionale dei Tumori, MilanoPhase 2
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)Zogenix, Inc.Phase 3
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)Modis Therapeutics, Inc.Phase 3

See all Deoxythymidine clinical trials

Clinical Trial Summary for Deoxythymidine

Top disease conditions for Deoxythymidine
Top clinical trial sponsors for Deoxythymidine

See all Deoxythymidine clinical trials

US Patents for Deoxythymidine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Deoxythymidine See Plans and Pricing Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus Seattle Genetics, Inc. (Bothell, WA) See Plans and Pricing
Deoxythymidine See Plans and Pricing Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease Axovant Sciences GmbH (Basel, CH) See Plans and Pricing
Deoxythymidine See Plans and Pricing Urethane-crosslinked biodegradable elastomers Massachusetts Institute of Technology (Cambridge, MA) The Brigham and Women's Hospital, Inc. (Boston, MA) Biocant-Center of Innovation and Biotechnology (Cantanhede, PT) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Deoxythymidine

Drugname Country Document Number Estimated Expiration Related US Patent
Deoxythymidine Canada CA2739250 2028-10-01 See Plans and Pricing
Deoxythymidine Canada CA2813743 2028-10-01 See Plans and Pricing
Deoxythymidine Canada CA2993404 2028-10-01 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Dow
McKesson
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.